Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression and Prognostic Value of CD80 and CD86 in the Tumor Microenvironment of Newly Diagnosed Glioblastoma

13 Jan 2022

Abstract excerpt

ABSTRACT: Background: Strategies to modulate the tumor microenvironment (TME) have opened new therapeutic avenues with dramatic yet heterogeneous intertumoral efficacy in multiple cancers, including glioblastomas (GBMs). Therefore, investigating molecular actors of TME may help understand the interactions between tumor cells and TME. Immune checkpoint proteins such as a Cluster of Differentiation 80 (CD80) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35022089
DOI: 10.1017/cjn.2022.5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression and Prognostic Value of CD80 and CD86 in the Tumor Microenvironment of Newly Diagnosed GlioblastomaPMID 35022089Read ↗

Identification of CD73 as a Novel Biomarker Encompassing the Tumor Microenvironment, Prognosis, and Therapeutic Responses in Various CancersSemantic proximity Read ↗

Molecular Insights and Prognosis Associated With RBM8A in GlioblastomaSemantic proximity Read ↗

Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trialsSemantic proximity Read ↗

Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic playersSemantic proximity Read ↗

Molecular Heterogeneity and Immunosuppressive Microenvironment in GlioblastomaSemantic proximity Read ↗

Identification of EMT-related gene signatures in glioblastoma to aid immunotherapy and prognosisSemantic proximity Read ↗

Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy developmentSemantic proximity Read ↗

TMEM106B in Glioma: Diagnostic Potential and Mechanistic ImplicationsSemantic proximity Read ↗

A Novel MALT1-related Immune Prognostic Signature and Targeted Drug Screening for GlioblastomaSemantic proximity Read ↗

Immune-related lncRNAs signature and radiomics signature predict the prognosis and immune microenvironment of glioblastoma multiformeSemantic proximity Read ↗

Immunogenetics of glioblastoma: the future of personalized patient managementSemantic proximity Read ↗

Mining TCGA database for genes of prognostic value in glioblastoma microenvironmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.